STOCK TITAN

Gain Therapeutics to Participate at Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Gain Therapeutics, a clinical-stage biotechnology company, announced participation in two upcoming investor conferences. Gene Mack, interim CEO and CFO, will represent the company at the 3rd Annual ROTH Healthcare Opportunities Conference on October 9, engaging in one-on-one meetings and a panel on 'Emerging Frontiers in Neuroscience'. He will also attend the 2024 Maxim Healthcare Virtual Summit on October 15, participating in a fireside chat with Jason McCarthy, Ph.D., from Maxim Group. Interested attendees can sign up on M-Vest for updates.

Gain Therapeutics, un'azienda biotecnologica in fase clinica, ha annunciato la sua partecipazione a due prossime conferenze per investitori. Gene Mack, CEO e CFO ad interim, rappresenterà l'azienda alla 3ª Conferenza Annuale ROTH sulle Opportunità Sanitarie il 9 ottobre, partecipando a incontri individuali e a un panel su 'Frontiere Emergenti nella Neuroscienza'. Parteciperà anche al Summit Virtuale Maxim Healthcare 2024 il 15 ottobre, prendendo parte a una conversazione informale con Jason McCarthy, Ph.D., del Maxim Group. Gli interessati possono iscriversi su M-Vest per aggiornamenti.

Gain Therapeutics, una empresa biotecnológica en etapa clínica, anunció su participación en dos próximas conferencias para inversores. Gene Mack, CEO y CFO interino, representará a la empresa en la 3ª Conferencia Anual ROTH de Oportunidades en el Sector Salud el 9 de octubre, participando en reuniones individuales y en un panel sobre 'Frentes Emergentes en Neurociencia'. También asistirá al Summit Virtual de Maxim Healthcare 2024 el 15 de octubre, participando en una charla informal con Jason McCarthy, Ph.D., del Maxim Group. Los asistentes interesados pueden registrarse en M-Vest para recibir actualizaciones.

Gain Therapeutics, 임상 단계의 생명공학 회사가 두 개의 다가오는 투자자 회의에 참여한다고 발표했습니다. Gene Mack, 임시 CEO이자 CFO가 제3회 연례 ROTH 헬스케어 기회 회의10월 9일에 참석하여 일대일 미팅 및 '신경과학의 새로운 경계'라는 주제의 패널에 참여할 것입니다. 그는 또한 2024 Maxim Healthcare 가상 정상 회의10월 15일에 참석하여 Maxim Group의 Jason McCarthy, Ph.D.와 대화에 참여할 것입니다. 관심 있는 참석자는 M-Vest에서 업데이트를 위해 등록할 수 있습니다.

Gain Therapeutics, une entreprise de biotechnologie en phase clinique, a annoncé sa participation à deux prochains conférences pour investisseurs. Gene Mack, PDG et CFO par intérim, représentera l'entreprise à la 3e Conférence Annuelle ROTH sur les Opportunités en Santé le 9 octobre, participant à des réunions en tête-à-tête et à un panel sur 'Nouvelles Frontières en Neurosciences'. Il assistera également au Sommet Virtuel Maxim Healthcare 2024 le 15 octobre, prenant part à une conversation informelle avec Jason McCarthy, Ph.D., du Maxim Group. Les participants intéressés peuvent s'inscrire sur M-Vest pour des mises à jour.

Gain Therapeutics, ein biopharmazeutisches Unternehmen in der klinischen Phase, hat die Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt. Gene Mack, Interim-CEO und CFO, wird das Unternehmen bei der 3. jährlichen ROTH Healthcare Opportunities Conference am 9. Oktober vertreten, wo er an Einzelgesprächen und einem Panel über 'Aufkommende Grenzen in der Neurowissenschaft' teilnehmen wird. Er wird auch am 2024 Maxim Healthcare Virtual Summit am 15. Oktober teilnehmen und einen informellen Austausch mit Jason McCarthy, Ph.D., von Maxim Group führen. Interessierte Teilnehmer können sich bei M-Vest für Aktualisierungen anmelden.

Positive
  • None.
Negative
  • None.

BETHESDA, Md., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, interim Chief Executive Officer and current Chief Financial Officer of Gain, will participate in two upcoming investor conferences:

  • 3rd Annual ROTH Healthcare Opportunities Conference on Wednesday, October 9.
    • Gene Mack will participate in one-on-one meetings as well as the themed industry panel, “Emerging Frontiers in Neuroscience”.
  • 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15 at 12pm ET.
    • Gene Mack will participate in a fireside chat with Jason McCarthy, Ph.D., Senior Managing Director and Head of Biotechnology Research at Maxim Group. To attend, sign up to become an M-Vest member and stay tuned for more updates.

About Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate, GT-02287 is currently being evaluated for the treatment of Parkinson’s disease with or without a GBA1 mutation. Results from a Phase 1 study of GT-02287 in healthy volunteers demonstrated favorable safety and tolerability, plasma exposure in the projected therapeutic range, CNS exposure, and target engagement and modulation of GCase enzyme.

Gain’s unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced Magellan™ platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology.

Forward-Looking Statements
This release contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as “believes,” “expects,” “anticipates,” “intends,” “will,” “may,” “should,” or similar expressions. These forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, risks associated with market conditions and the satisfaction of customary closing conditions related to the offering and uncertainties related to the offerings and the use of proceeds from the offerings. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company’s business in general, please refer to the Company’s prospectus supplement to be filed with the SEC, and the documents incorporated by reference therein, including the Company’s Form 10-K for the year ended December 31, 2023 and Form 10-Q for the quarter ended June 30, 2024.
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contacts:
Apaar Jammu and Chuck Padala
ajammu@gaintherapeutics.com
chuck@lifesciadvisors.com

Media Contacts:
Russo Partners
Nic Johnson and Elio Ambrosio
nic.johnson@russopartnersllc.com
elio.ambrosio@russopartnersllc.com
(760) 846-9256


FAQ

What conferences will Gain Therapeutics participate in?

Gain Therapeutics will participate in the 3rd Annual ROTH Healthcare Opportunities Conference on October 9 and the 2024 Maxim Healthcare Virtual Summit on October 15.

When is the 3rd Annual ROTH Healthcare Opportunities Conference?

The 3rd Annual ROTH Healthcare Opportunities Conference will be held on October 9.

Who will represent Gain Therapeutics at the upcoming conferences?

Gene Mack, interim CEO and CFO of Gain Therapeutics, will represent the company at the upcoming conferences.

What will Gene Mack discuss at the 2024 Maxim Healthcare Virtual Summit?

Gene Mack will participate in a fireside chat with Jason McCarthy, Ph.D., at the 2024 Maxim Healthcare Virtual Summit.

How can I attend the 2024 Maxim Healthcare Virtual Summit?

To attend the 2024 Maxim Healthcare Virtual Summit, sign up to become an M-Vest member.

Gain Therapeutics, Inc.

NASDAQ:GANX

GANX Rankings

GANX Latest News

GANX Stock Data

46.95M
25.22M
5.09%
7.96%
2.58%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BETHESDA